Public health measures to control the spread of antimicrobial resistance in Neisseria gonorrhoeae in men who have sex with men

Epidemiology and Infection

Volumn 143, Issue 8, 2015, Pages 1575-1584

  Xiridou, M ^a   Soetens, L C ^a   Koedijk, F D H ^a,b   Van Der Sande, M A B ^a,c   Wallinga, J ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b Youth Healthcare Services   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antibiotics; antimicrobial agents; antimicrobial resistance; gonorrhoea; gonorrhoea prevention and control; mathematical model; men who have sex with men

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG SUBSTITUTION; GONORRHEA; HIGH RISK BEHAVIOR; HUMAN; INFECTION CONTROL; MALE; MALE HOMOSEXUALITY; NEISSERIA GONORRHOEAE; PUBLIC HEALTH; THEORETICAL MODEL; TRANSMISSION;

ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, BACTERIAL; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; GONORRHEA; HOMOSEXUALITY, MALE; HUMANS; MALE; MODELS, THEORETICAL; NEISSERIA GONORRHOEAE; PUBLIC HEALTH; RISK-TAKING;

EID: 84929150861     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268814002519     Document Type: Article

References (38)

1. World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. 2012 (http://whqlibdoc.who.int/publications/2012/9789241503501-eng.pdf).
2. Lewis DA. The gonococcus fights back: is this time a knock out? Sexually Transmitted Infections 2010; 86: 415-421.
3. Koedijk F, et al. Increasing trend in gonococcal resistance to ciprofloxacin in The Netherlands, 2006-8. Sexually Transmitted Infections 2010; 86: 41-45.
4. Health Protection Agency. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 2011 Report. HPA Gateway reference: HPA12-03. London, 2012.
5. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2010; Oral cephalosporins no longer a recommended treatment for gonococcal infections. Morbidity and Mortality Weekly Report 2012; 61: 590-594.
6. Deguchi T, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at at 6-h interval. Journal of Infection and Chemotherapy 2003; 9: 35-39.
7. Unemo M, et al. High-level cefixime- and ceftriaxone- resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrobial Agents and Chemotherapy 2012; 56 : 1273-80.
8. Ohnishi M, et al . Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhoea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrobial Agents and Chemotherapy 2011; 55: 3538-3545.
9. Cámara J, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. Journal of Antimicrobial Chemotherapy 2012; 67: 1858-1860.
10. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proceedings of the National Academy of Sciences USA 1997; 94: 12106-12111.
11. Chan CH, McCabe CJ, Fisman DN. Core groups, antimicrobial resistance and rebound in gonorrhoea in North America. Sexually Transmitted Infections 2012; 88: 200-204.
12. Turner KME, Garnett GP. The impact of the phase of an epidemic of sexually transmitted infection on the evolution of the organism. Sexually Transmitted Infections 2002; 78 (Suppl. I): i20-i30.
13. Ferguson NM, et al. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. Journal of Antimicrobial Chemotherapy 2003; 51: 977-990.
14. Kardas-Sloma L, et al. Antibiotic reduction campaigns do not necessarily decrease bacterial resistance: the example of methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2013; 57: 4410-4416.
15. Lipsitch M, Bergstrom CT, Levin BR. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proceedings of the National Academy of Sciences USA 2000; 97: 1938-1943.
16. Handel A, Regoes RR, Antia R. The role of compensatory mutations in the emergence of drug resistance. PLoS Computational Biology 2006; 2: e137.
17. Hall RJ, Gubbins S, Gilligan CA. Invasion of drug and pesticide resistance is determined by a trade-off between treatment efficacy and relative fitness. Bulletin of Mathematical Biology 2004; 66: 825-840.
18. Kouyos RD, zur Wiesch PA, Bonhoeffer S. Informed switching strongly decreases the prevalence of antibiotic resistance in hospital wards. PLoS Computational Biology 2011; 7: e1001094.
19. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Medicine 2006; 3: e124.
20. Lipsitch M, Levin BR. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. International Journal Tuberculosis Lung Diseases 1998; 2: 187-199.
21. Austin DJ, Kakehashi M, Anderson RM. The transmission dynamics of antibiotic-resistant bacteria: the relationship between resistance in commensal organisms and antibiotic consumption. Proceedings of the Royal Society of London, Series B 1997; 264: 1629-1638.
22. Heathcote HW, Yorke JA. Gonorrhoea transmission dynamics and control. Lecture Notes in Biomathematics 56. 1984, New York: Springer.
23. Garnett GP, et al. The transmission dynamics of gonorrhoea: modelling the reported behavior of infected patients from Newark, New Jersey. Philosophical Transactions of the Royal Society of London, Series B 1999; 354: 787-797.
24. Kolader ME, et al. Molecular epidemiology of Neisseria gonorrhoeae in Amsterdam, the Netherlands, shows distinct heterosexual and homosexual networks. Journal of Clinical Microbiology 2006; 44: 2689-2697.
25. Grad YH, et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. Lancet Infectious Diseases 2014; 14: 220-226.
26. Xiridou M, et al. Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men. BMC Infectious Diseases 2013; 13: 436.
27. Schorer Foundation. Schorer Monitor 2006, 2007, 2008, 2009, 2010, 2011.
28. National Institute of Public Health and the Environment. Sexually transmitted infections, including HIV, in the Netherlands in 2011. RIVM report no. 201051001. Bilthoven, The Netherlands, 2012.
29. World Health Organization. Guidelines for the Management of Sexually Transmitted Diseases. Geneva: World Health Organization, 2003.
30. Koedijk FDH, et al. Gonococci change faster than prescription-behaviour [in Dutch]. Nederlands Tijdschrift van Geneeskunde 2013; 157: A5642.
31. Parienti J, et al. Hospital-wide modification of fluoro-quinolone policy and meticillin-resistant Staphylococcus aureus rates: a 10-year interrupted timeseries analysis. Journal of Hospital Infection 2011; 78: 118-122.
32. Hooper RR, et al. Cohort study of venereal disease. I: the risk of gonorrhoea transmission from infected women to men. American Journal of Epidemiology 1978; 108: 136-144.
33. nd edn, 1990, New York: McGraw-Hill.
34. Sherrard J, Barlow D. Gonorrhoea in men: clinical and diagnostic aspects. Genitourinary Medicine 1996; 72: 422-426.
35. Trindade S, et al. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genetics 2009; 5: e1000578.
36. Reynolds MG. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 2000; 156: 1471-1481.
37. Maisnier-Patin S, et al . Compensatory adaptation to the delerious effect of antibiotic resistance in Salmonella typhimurium. Molecular Microbiology 2002; 2: 355-366.
38. Conti S, et al. Modeling of the HIV infection epidemic in the Netherlands: a multi-parameter evidence synthesis approach. Annals of Applied Statistics 2011; 5: 2359-2384.